Abstract
Neurofibromin (NF1) mutations cause neurofibromatosis type 1 and drive numerous cancers, including breast and brain tumors. NF1 inhibits cellular proliferation through its guanosine triphosphatase-activating protein (GAP) activity against rat sarcoma (RAS). In the present study, cryo-electron microscope studies reveal that the human ~640-kDa NF1 homodimer features a gigantic 30 × 10 nm array of α-helices that form a core lemniscate-shaped scaffold. Three-dimensional variability analysis captured the catalytic GAP-related domain and lipid-binding SEC-PH domains positioned against the core scaffold in a closed, autoinhibited conformation. We postulate that interaction with the plasma membrane may release the closed conformation to promote RAS inactivation. Our structural data further allow us to map the location of disease-associated NF1 variants and provide a long-sought-after structural explanation for the extreme susceptibility of the molecule to loss-of-function mutations. Collectively these findings present potential new routes for therapeutic modulation of the RAS pathway.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The 3D cryo-EM density maps were deposited into the Electron Microscopy Data Bank (https://www.ebi.ac.uk/pdbe/emdb) under accession nos. EMDB-23930 (NF1 homodimer core), EMDB-23924 (NF1 wing) and EMDB-23929 (NF1 autoinhibited state). The coordinates were deposited in the PDB (https://www.rcsb.org) with accession nos. 7MP6 (NF1 homodimer core), 7MOC (NF1 wing) and 7MP5 (NF1 autoinhibited state). The coordinates used in analysis (PDB accession nos. 6V65 and 3PG7) are available at the PDB (https://www.rcsb.org). MS proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE57 partner repository with the accession no. PXD023593 (refs. 58,59). Source data are provided with this paper.
References
Li, S., Balmain, A. & Counter, C. M. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat. Rev. Cancer 18, 767–777 (2018).
Shaw, R. J. & Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424–430 (2006).
Cichowski, K. & Jacks, T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104, 593–604 (2001).
Ratner, N. & Miller, S. J. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat. Rev. Cancer 15, 290–301 (2015).
Gutmann, D. H. et al. Neurofibromatosis type 1. Nat. Rev. Dis. Prim. 3, 17004 (2017).
Consortium, ITP-CAoWG. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175–180 (2017).
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012).
Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–477 (2013).
Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).
Kang, E. et al. Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types. J. Hum. Genet 65, 79–89 (2020).
Basu, T. N. et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356, 713–715 (1992).
Brems, H., Beert, E., de Ravel, T. & Legius, E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 10, 508–515 (2009).
Johannessen, C. M. et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl Acad. Sci. USA 102, 8573–8578 (2005).
Cui, Y. et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135, 549–560 (2008).
Holzel, M. et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142, 218–229 (2010).
Wolman, M. A. et al. Modulation of cAMP and ras signaling pathways improves distinct behavioral deficits in a zebrafish model of neurofibromatosis type 1. Cell Rep. 8, 1265–1270 (2014).
Sherekar, M. et al. Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. J. Biol. Chem. 295, 1105–1119 (2020).
Yan, W. et al. Structural insights into the SPRED1-neurofibromin-KRAS complex and disruption of SPRED1-neurofibromin interaction by oncogenic EGFR. Cell Rep. 32, 107909 (2020).
D’Angelo, I., Welti, S., Bonneau, F. & Scheffzek, K. A novel bipartite phospholipid-binding module in the neurofibromatosis type 1 protein. EMBO Rep. 7, 174–179 (2006).
Rabara, D. et al. KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis. Proc. Natl Acad. Sci. USA 116, 22122–22131 (2019).
Scheffzek, K. et al. Structural analysis of the GAP-related domain from neurofibromin and its implications. EMBO J. 17, 4313–4327 (1998).
Xie, K. et al. NF1 is a direct G protein effector essential for opioid signaling to ras in the striatum. Curr. Biol. 26, 2992–3003 (2016).
Zheng, Z. Y. et al. Neurofibromin is an estrogen receptor-alpha transcriptional co-repressor in breast cancer. Cancer Cell 37, 387–402 e7 (2020).
Koliou, X., Fedonidis, C., Kalpachidou, T. & Mangoura, D. Nuclear import mechanism of neurofibromin for localization on the spindle and function in chromosome congression. J. Neurochem. 136, 78–91 (2016).
Feng, L. et al. PKA phosphorylation and 14-3-3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin. FEBS Lett. 557, 275–282 (2004).
Mangoura, D. et al. Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells. Oncogene 25, 735–745 (2006).
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
Yoshimura, S. H. & Hirano, T. HEAT repeats—versatile arrays of amphiphilic helices working in crowded environments? J. Cell Sci. 129, 3963–3970 (2016).
Dunzendorfer-Matt, T., Mercado, E. L., Maly, K., McCormick, F. & Scheffzek, K. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation. Proc. Natl Acad. Sci. USA 113, 7497–7502 (2016).
Cali, F. et al. Mutation spectrum of NF1 gene in Italian patients with neurofibromatosis type 1 using Ion Torrent PGM platform. Eur. J. Med Genet 60, 93–99 (2017).
Girodon-Boulandet, E. et al. NF1 gene analysis focused on CpG-rich exons in a cohort of 93 patients with neurofibromatosis type 1. Hum. Mutat. 16, 274–275 (2000).
Violante, I. R. et al. GABA deficit in the visual cortex of patients with neurofibromatosis type 1: genotype–phenotype correlations and functional impact. Brain 136, 918–925 (2013).
Melloni, G. et al. Risk of optic pathway glioma in neurofibromatosis type 1: no evidence of genotype–phenotype correlations in a large independent cohort. Cancers 11, 1838 (2019).
van Minkelen, R. et al. A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnostics in the Netherlands. Clin. Genet 85, 318–327 (2014).
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
Tegunov, D. & Cramer, P. Real-time cryo-electron microscopy data preprocessing with Warp. Nat. Methods 16, 1146–1152 (2019).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
Rohou, A. & Grigorieff, N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216–221 (2015).
Wagner, T. et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. Commun. Biol. 2, 218 (2019).
Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).
Ramlaul, K., Palmer, C. M., Nakane, T. & Aylett, C. H. S. Mitigating local over-fitting during single particle reconstruction with SIDESPLITTER. J. Struct. Biol. 211, 107545 (2020).
Grant, T., Rohou, A. & Grigorieff, N. cisTEM, user-friendly software for single-particle image processing. eLife 7, e35383 (2018).
Tang, G. et al. EMAN2: an extensible image processing suite for electron microscopy. J. Struct. Biol. 157, 38–46 (2007).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).
Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D Struct. Biol. 74, 519–530 (2018).
Ellisdon, A. M., Dimitrova, L., Hurt, E. & Stewart, M. Structural basis for the assembly and nucleic acid binding of the TREX-2 transcription-export complex. Nat. Struct. Mol. Biol. 19, 328–336 (2012).
Cramer, P. AlphaFold2 and the future of structural biology. Nat. Struct. Mol. Biol. 28, 704–705 (2021).
Yang, B. et al. Identification of cross-linked peptides from complex samples. Nat. Methods 9, 904–906 (2012).
Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. Genome Res. 19, 1639–1645 (2009).
Mondal, S., Hsiao, K. & Goueli, S. A. A homogenous bioluminescent system for measuring GTPase, GTPase activating protein, and guanine nucleotide exchange factor activities. Assay Drug Dev. Technol. 13, 444–455 (2015).
Schuck, P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys. J. 78, 1606–1619 (2000).
Laue, T. M., Shah, B., Ridgeway, T. M. & Pelletier, S. L. in Analytical Ultracentrifugation in Biochemistry and Polymer Science (eds Harding, S. E., et al.) pp. 90–125 (Royal Society of Chemistry, 1992).
Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 47, D442–D450 (2019).
Hornbeck, P. V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512–D520 (2015).
Ashkenazy, H. et al. ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids Res. 44, W344–W350 (2016).
Acknowledgements
M.L.H. is a Viertel Senior Medical Research Fellow supported by the Cross Family and the Frank Alexander Charitable Trusts. J.C.W. is an Australian Research Council Laureate Fellow and honorary Senior Principal Research Fellow, National Health and Medical Research Council of Australia (NHMRC). This research was supported by an Australian Government MRFF grant (no. MRF2010629 to A.M.E., M.L.H. and R.B.S.), an NHMRC project grant (no. APP1121029 to M.L.H.) and equipment funded by an Australian Research Council grant (no. LE170100016). C.B.J. thanks the Australian Government for their support by way of a Research Training Program stipend. We thank the Monash Ramaciotti Centre for Cryo-Electron Microscopy, a Node of Microscopy Australia, for the use of instruments and assistance. We also thank the office of the Vice-Provost for Research and Research Infrastructure at Monash University and of Bioplatforms Australia as part of the National Collaborative Research Infrastructure Strategy.
Author information
Authors and Affiliations
Contributions
A.M.E. and M.L.H. conceived the study. C.J.L. and L.D. performed cloning, protein expression and purification. L.D. performed GAP-activity assays, nDSF and ultracentrifugation experiments. C.J.L. prepared cryo-EM grids. C.J.L. and H.V. collected cryo-EM data. C.B-J., C.J.L. and A.M.E. processed cryo-EM data, and built and refined atomic models. L.D., C.H. and R.B.S. performed crosslinking and MS. C.J.L., C.B-J, L.D., J.C.W., M.L.H. and A.M.E. wrote and drafted the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Peer review information Nature Structural and Molecular Biology thanks Nancy Ratner and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Florian Ullrich was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 Purification and biochemical characterisation of the NF1 dimer.
a. Schematic of the inhibitory role of NF1 in RAS signaling. b. Select NF1 binding partners and cellular effectors are listed4. c. NF1 purifies as a single peak by size-exclusion chromatography. d. Purified recombinant NF1 is highly pure by SDS-PAGE. NF1 purity as assessed by SDS-PAGE was consistent for all purifications (at least 10) as shown in this representative gel. Lane A: molecular weight marker and Lane B: purified NF1 e. NF1 accelerates the hydrolysis of GTP by KRAS. Hydrolysis was measured using a GTPase-Glo kit (Promega) to detect the amount of GTP remaining in the reaction after incubation. ** p = 0.004 versus Ras-GTP alone, paired two-tailed t-test, n = 3 independent experiments. Symbols show values from independent experiments, bars show the mean and error bars show S.E.M. f. Sedimentation velocity analytical ultracentrifugation analysis indicates that NF1 likely forms a homodimer in solution (calculated molecular weight of 640 kDa, r.m.s.d. 0.004).
Extended Data Fig. 2 Cryo-EM summary and validation for the NF1 wing localized reconstruction.
a. A representative denoised micrograph of NF1 collected on a Talos Arctica 200 kV (1 of 2,675 micrographs). Scale bar = 100 nm. b. Selected 2D class averages of the NF1 dimer. Diffuse signal can be observed at the central interface corresponding to flexible GRD/SEC-PH domains. c. Select 2D class averages of symmetry expanded, localized reconstructions of a single NF1 dimer lobe. d. Angular distribution of the final localized reconstruction, shown beside is the corresponding orientation of the reconstruction for clarity. e. The NF1 dimer lobe coloured by local resolution. f. Distribution of voxels as a function of local resolution. The majority of voxels are resolved to a mode value of ~4.5 Å. g. The Fourier shell correlation plot estimates a global resolution of 4.5 Å.
Extended Data Fig. 3 Cryo-EM summary and validation for the reconstructions of NF1 autoinhibited and dimeric states.
a. Angular distribution of the autoinhibited NF1 localized reconstruction and b. local resolution analysis. c. Frequency distribution of voxels as a function of local resolution for the autoinhibited NF1 localized reconstruction. d. The Fourier shell correlation (FSC) plot estimates a global resolution of 5.6 Å. e. Map to model FSC, including local map to model FSCs for the GRD and PH-SEC domains. f, g, h. As in a, b, c. for the full NF1 homodimer. i. The Fourier shell correlation plot estimates a global resolution of 6.3 Å.
Extended Data Fig. 4 Cryo-EM data analysis and flowchart.
Initial cryo-EM analysis is indicated in purple. Subsequent analysis of the whole dataset give rise to a 6.3-Å reconstruction of the NF1 dimer (green). Symmetry expansion and signal subtraction were utilised to generate a focused refinement of a single NF1 lobe (light blue) to overcome substantial continuous conformational heterogeneity. The final 4.5-Å reconstruction was later fit into the NF1 dimer reconstruction to yield a composite map. Variational analysis revealed a small discrete population of NF1 particles with resolved GRD and SEC-PH domains (red) in an autoinhibited conformation.
Extended Data Fig. 5 Map to model.
a. Map-to-model fit of the SEC-PH domain (blue). b. Map-to-model fit of the GRD domain (green), clearly resolved secondary structure is evident. c. The autoinhibited conformation of NF1, GRD (green) and SEC-PH (blue) domains are well resolved against the scaffold. d. The sharpened 4.5-Å reconstruction of the core NF1 scaffold and select regions of density illustrating resolved side chains.
Extended Data Fig. 6 Cross-linking mass spectrometry of NF1.
a. Cross-linking mass spectrometry identified a total of 174 BS2G cross-links and 72 BS3 cross-links within the NF1 dimer. b. Mapping of the BS2G cross-links onto the NF1 structure revealed that the cross-links mapped to allowable regions of the NF1 model. Cα carbons of cross-linked residues are shown as spheres and lines indicate cross-linked residues. Cross-links are shown for a single chain only for clarity. c. Circos plot highlighting all BS3 and BS2G cross-links observed between the GRD domain and the rest of the NF1 molecule. GRD cross-linked regions map remarkably well to the two known NF1 phosphor-regulatory regions58. Known NF1 phosphorylation sites58 are indicated as dashed red lines on the inside of the Circos plot. d. Although these phosphor-regulatory regions are too flexible to appear in the cryo-EM maps, they are each situated adjacent to the GRDs and appear poised to further regulate either the conformation of the GRD or membrane binding capacity. Structural representation of the NF1 surface with the GRD and SEC-PH domains in cartoon format. The Cα carbon of the exit (C2432) and entry (P2596) residue of the main phosphor-regulatory loop are indicated as yellow spheres. The Cα carbon of the final resolved residue of the C-terminus (L2726) is also indicated as a yellow sphere. Cα carbons on the GRD that cross-link to the phosphor-regulatory loops are indicated as pink spheres.
Extended Data Fig. 7 Surface conservation of NF1.
NF1 surface conservation analyzed using ConSurf59. a. The NF1 dimer with surface conservation mapped to a single chain. b. NF1 rotated 180° to show surface conservation of the second chain. c. A single NF1 chain displayed to show the conserved central interface.
Extended Data Fig. 8 Previously published NF1 pull-down experiments19 mapped onto the NF1 cryo-EM structure are consistent with observed structural interfaces.
a. Overall dimer rendered as pipes and planks, coloured according to NF1 truncations (coloured grey, red, blue, yellow, green and magenta). b. Cartoon model of NF1 where each NF1 fragment is represented by a letter, coloured consistently with the structural representation. Intra- and intermolecular interactions are depicted as a solid or dashed lines, respectively. Flexible long-range interactions observed by cross-linking mass spectrometry are not depicted in the structure (blue dashed line). Interactions observed only in the autoinhibited conformation between the GRD (blue) and the NF1 core (green) are depicted (red dashed line). c. Summary table that outlines pull down experiments previously published by Sherekar et al.19 of NF1 fragments (labelled according to b.). Green entries represent successful complexes between bait and fish fragments, blue entries (underlined) represent partial or weak complexes and red entries (strikethrough) failed to interact. d. The NF1 structure with Cα atoms of residues mutated in neurofibromatosis type 1 (blue) or cancer (red) displayed as spheres. All neurofibromatosis type 1 mutations from the indicated studies12,32 are displayed and for clarity cancer-associated mutations are only displayed if they were in the COSMIC11 database three or more times.
Extended Data Fig. 9 Biophysical analysis of select NF1 mutants.
a. WT purifies as a single homodimer peak by size-exclusion chromatography. b. L844F is observed in cancer and neurofibromatosis type 126. L844F fails to express at levels detectable by Ni-NTA pull down and size-exclusion chromatography. c. Neurofibromatosis type 1 mutation L1834R34 has reduced expression compared to WT and elutes with a broad profile with a clear shoulder on the main dimer peak consistent with dimer and monomer formation. d. Neurofibromatosis type 1 mutation N1840K35 has severely reduced expression levels. e. R1849Q is observed in cancers and forms a single dimeric peak by size-exclusion chromatography and SDS-PAGE analysis. f. Neurofibromatosis type 1 mutation L2104R27 has reduced expression levels compared to WT and a broad elution profile consistent with dimer and monomer formation. NF1 WT and mutant elution profiles as assessed by SDS-PAGE (lower panels) were consistent for all purifications (n = 2 independent purifications). g. nDSF-derived apparent melting temperature (Tm) from n = 3 independent experiments for WT and all mutants except for L2104R where apparent melting temperature was derived from n = 2 independent experiments. Symbols show values from independent experiments, bars show the mean and error bars show S.E.M. (except for L2104R where no error bars are displayed). Ultracentrifuge analysis of L1834R fractions h. 12-14 mL and i. 14-17 mL (see panel c.). j. L1834R SDS-PAGE after ultracentrifuge analysis demonstrates clear breakdown. This is more pronounced in the monomer fraction (compare panels c. to j.). k. Fractions 12-14 mL and l. 14-17 mL (see panel f.). m. SDS-PAGE analysis of L2104R after analytical ultracentrifuge analysis also demonstrates clear breakdown of L2104R that is more pronounced in the monomer fraction (compare panels f. to m.). Data indicate a loss of stability in L1834R and L2104R mutants that is more pronounced in the monomer fractions.
Supplementary information
Supplementary Information
Supplementary Fig. 1.
Supplementary Video 1
The NF1 dimer structure.
Supplementary Video 2
The continuous conformational heterogeneity of NF1.
Supplementary Data 1
Observed NF1 crosslinks.
Source data
Source Data Fig. 4
Source data for mutation frequency.
Source Data Extended Data Fig. 9
Unprocessed sodium dodecylsulfate–polyacrylamide gel electrophoresis.
Rights and permissions
About this article
Cite this article
Lupton, C.J., Bayly-Jones, C., D’Andrea, L. et al. The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1. Nat Struct Mol Biol 28, 982–988 (2021). https://doi.org/10.1038/s41594-021-00687-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41594-021-00687-2
This article is cited by
-
Schwann cell derived pleiotrophin stimulates fibroblast for proliferation and excessive collagen deposition in plexiform neurofibroma
Cancer Gene Therapy (2024)
-
Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance
Nature Communications (2024)
-
The oncogenic role of NF1 in gallbladder cancer through regulation of YAP1 stability by direct interaction with YAP1
Journal of Translational Medicine (2023)
-
The therapeutic potential of neurofibromin signaling pathways and binding partners
Communications Biology (2023)
-
New insights into the molecular basis of spinal neurofibromatosis type 1
European Journal of Human Genetics (2023)